*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Please contact James Dahlman with questions.
Summary Sentence: Julie Sunderland - Co-Founder, Biomatics Capital
Full Summary: Julie Sunderland - Co-Founder, Biomatics Capital
Gene Editing / Therapy Seminar Series 2021Julie Sunderland
Co-Founder
Biomatics Capital
Join this virtual event via BlueJeans
BIOGRAPHY
Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals. Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs. Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies. Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, Compass Therapeutics, eGenesis and Verana Health.
The Gene Editing / Gene Therapy Seminar Series features leading academic, translational, and investor speakers in e-talks through the summer and fall.
